Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds

PLoS Neglected Tropical Diseases

Volumn 4, Issue 5, 2010, Pages

  Siqueira Neto, Jair L ^a   Song, Ok Ryul ^b   Oh, Hyunrim ^b   Sohn, Jeong Hun ^b   Yang, Gyongseon ^a   Nam, Jiyoun ^b   Jang, Jiyeon ^b   Cechetto, Jonathan ^b   Lee, Chang Bok ^b   Moon, Seunghyun ^c   Genovesio, Auguste ^c   Chatelain, Eric ^d   Christophe, Thierry ^b   Freitas Junior, Lucio H ^a  

^a Institute Pasteur Korea   (South Korea)

^b Institut Pasteur Korea   (South Korea)

^c Image Mining Group   (South Korea)

^d Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; ANTIPROTOZOAL AGENT; CA 272; CG 170; CH 872; CYTOCHROME P450; ETHIDIUM BROMIDE; MILTEFOSINE; NJ 231; PAROMOMYCIN; TE 122; UNCLASSIFIED DRUG;

AMASTIGOTE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; NONHUMAN; PROMASTIGOTE; RAT; VALIDATION PROCESS; CELL LINE; DRUG EFFECT; DRUG SCREENING; DRUG STABILITY; ENZYMOLOGY; LEISHMANIA; LIVER MICROSOME; MACROPHAGE; METABOLISM; METHODOLOGY; MICROBIAL VIABILITY; MONOCYTE; PARASITOLOGY;

ANTIPROTOZOAL AGENTS; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HUMANS; LEISHMANIA; MACROPHAGES; MICROBIAL VIABILITY; MICROSOMES, LIVER; MONOCYTES;

EID: 77955284688     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000675     Document Type: Article

References (34)

1. Piscopo TV, Mallia Azzopardi C (2007) Leishmaniasis. Postgrad Med J 83: 649-657.
2. WHO (1990) World Health Organ. Tech Rep Ser 793: 1-158.
3. Ashford RW, Desjeux P, Deraadt P (1992) Estimation of population at risk of infection and number of cases of Leishmaniasis. Parasitol Today 8: 104-105.
4. King CH, Bertino AM (2008) Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. PLoS Negl Trop Dis 2: e209.
5. Kolaczinski JH, Reithinger R, Worku DT, Ocheng A, Kasimiro J, et al. (2008) Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda. Int J Epidemiol 37: 344-352.
6. Desjeux P (2004) Leishmaniasis. Nat Rev Microbiol 2: 692.
7. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, et al. (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7: 581-596.
8. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873-882.
9. Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126.
10. Nwaka S, Hudson A (2006) Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 5: 941-955.
11. Davis AJ, Murray HW, Handman E (2004) Drugs against leishmaniasis: a synergy of technology and partnerships. Trends Parasitol 20: 73-76.
12. Sereno D, Cordeiro da Silva A, Mathieu-Daude F, Ouaissi A (2007) Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitol Int 56: 3-7.
13. Mikus J, Steverding D (2000) A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol Int 48: 265-269.
14. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, et al. (2005) The genome of the kinetoplastid parasite, Leishmania major. Science 309: 436-442.
15. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
16. Zhang JH, Chung TD, Oldenburg KR (2000) Confirmation of primary active substances from high throughput screening of chemical and biological populations: a statistical approach and practical considerations. J Comb Chem 2: 258-265.
17. Crespi CL, Miller VP, Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248: 188-190.
18. Vermeersch M, da Luz RI, Toté K, Timmermans JP, Cos P, et al. (2009) In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 53: 3855-3859.
19. Jhingran A, Chawla B, Saxena S, Barrett MP, Madhubala R (2009) Paromomycin: uptake and resistance in Leishmania donovani. Mol Biochem Parasitol 164: 111-117.
20. Junghae M, Raynes JG (2002) Activation of p38 mitogen-activated protein kinase attenuates Leishmania donovani infection in macrophages. Infect Immun 70: 5026-5035.
21. Bakunova SM, Bakunov SA, Patrick DA, Kumar EV, Ohemeng KA, et al. (2009) Structure-activity study of pentamidine analogues as antiprotozoal agents. J Med Chem 52: 2016-2035.
22. Ghosh AK, Rakshit MM, Ghosh DK (1983) Effect of berberine chloride on Leishmania donovani. Indian J Med Res 78: 407-416.
23. Tiuman TS, Ueda-Nakamura T, Garcia Cortez DA, Dias Filho BP, Morgado-Diaz JA, et al. (2005) Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother 49: 176-182.
24. Neal RA, van Bueren J, Hooper G (1988) The activity of nitrofurazone and furazolidone against Leishmania donovani, L. major and L. enriettii in vitro and in vivo. Ann Trop Med Parasitol 82: 453-456.
25. Haberkorn A (1979) The effect of nifurtimox on experimental infections with trypanosomatidae other than Trypanosoma cruzi. Zentralbl Bakteriol Orig A 244: 331-338.
26. Gebre-Hiwot A, Tadesse G, Croft SL, Frommel D (1992) An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1. Acta Trop 51: 237-245.
27. Croft SL, Yardley V, Kendrick H (2002) Drug sensitivity of Leishmania species: some unresolved problems. Trans R Soc Trop Med Hyg 96 Suppl 1: S127-129.
28. Stark K, Guengerich FP (2007) Characterization of orphan human cytochromes P450. Drug Metab Rev 39: 627-637.
29. Singh SS (2006) Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 7: 165-182.
30. St George S, Bishop JV, Titus RG, Selitrennikoff CP (2006) Novel compounds active against Leishmania major. Antimicrob Agents Chemother 50: 474-479.
31. Sharlow ER, Close D, Shun T, Leimgruber S, Reed R, et al. (2009) Identification of potent chemotypes targeting Leishmania major using a highthroughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis 3: e540.
32. Vieira NC, Herrenknecht C, Vacus J, Fournet A, Bories C, et al. (2008) Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials. Biomed Pharmacother 62: 684-689.
33. Kinnamon KE, Steck EA, Loizeaux PS, Hanson WL, Chapman WL, Jr., et al. (1978) The antileishmanial activity of lepidines. Am J Trop Med Hyg 27: 751-757.
34. Jha TK, Sundar S, Thakur CP, Felton JM, Sabin AJ, et al. (2005) A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 73: 1005-1011.